glp-1 for kidney disease Design and discovery of a highly potent ultralong-acting and glucagon co-agonist attenuating renal fibrosis Kidney Outcomes With Glucagon-Like Peptide-1
Description
Innovations in drug delivery methods and sustained R&D investments further enhance market potential

Thats where tools lik

This review summarises recent advances in the understanding of diabetic gastroparesis, with an emphasis on the current therapies that influence GE, and the bidirectional relationship between glycaemic control and GE.

Alcohol worsens GI, non-diabetics identical, urinary/eye/mental effects covered.
Tongue pain, dryness, or white patches

Result: GLP-1s lowered osteoporosis risk (31% reduction)
